Alessandra Felici
Overview
Explore the profile of Alessandra Felici including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
443
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bracarda S, Bamias A, Casper J, Negrier S, Sella A, Staehler M, et al.
Clin Genitourin Cancer
. 2019 May;
17(3):e689-e703.
PMID: 31072748
Background: Axitinib resulted in significantly longer progression-free survival (PFS) versus sorafenib in patients with metastatic renal-cell carcinoma (mRCC) previously treated with sunitinib in the AXIS trial. We report post hoc...
2.
Giacinti S, Carlini P, Roberto M, Bassanelli M, Strigari L, Pavese F, et al.
Anticancer Drugs
. 2016 Oct;
28(1):110-115.
PMID: 27763885
Abiraterone acetate (AA) demonstrated its efficacy in the treatment of patients with metastatic castration resistance prostate cancer (mCRPC) in predocetaxel and postdocetaxel setting. However, we learn from pivotal studies that...
3.
Bracarda S, Caserta C, Galli L, Carlini P, Pastina I, Sisani M, et al.
Future Oncol
. 2015 Oct;
11(22):3083-90.
PMID: 26437324
Background: We evaluated the possible advantages of a docetaxel (DCT) rechallenge strategy in metastatic castration-resistant prostate cancer (mCRPC) patients, also given the possible earlier positioning of this treatment option in...
4.
Iacovelli R, Santini D, Rizzo M, Felici A, Santoni M, Verzoni E, et al.
Can Urol Assoc J
. 2015 Aug;
9(7-8):263-7.
PMID: 26316911
Introduction: Treatment of metastatic renal cell carcinoma (mRCC) has improved with the use of targeted therapies, but bone metastases continue to be negative prognostic factor. Methods: Patients with mRCC treated...
5.
Pantano F, Santoni M, Procopio G, Rizzo M, Iacovelli R, Porta C, et al.
PLoS One
. 2015 Apr;
10(4):e0120427.
PMID: 25885920
Background: Everolimus is a mammalian target of rapamycin (mTOR) inhibitor approved for the treatment of metastatic renal cell carcinoma (mRCC). We aimed to assess the association between the baseline values...
6.
Santoni M, Conti A, Procopio G, Porta C, Ibrahim T, Barni S, et al.
J Exp Clin Cancer Res
. 2015 Feb;
34:10.
PMID: 25651794
Purpose: Aim of this study was to investigate for the presence of existing prognostic factors in patients with bone metastases (BMs) from RCC since bone represents an unfavorable site of...
7.
Procopio G, Derosa L, Gernone A, Morelli F, Sava T, Zustovich F, et al.
Future Oncol
. 2014 Mar;
10(10):1741-50.
PMID: 24641206
Aim: The Italian Retrospective Analysis of Sorafenib as First or Second Target Therapy study assessed the efficacy and safety of sorafenib in metastatic renal cell carcinoma patients treated in the...
8.
Santini D, Procopio G, Porta C, Ibrahim T, Barni S, Mazzara C, et al.
PLoS One
. 2014 Jan;
8(12):e83026.
PMID: 24386138
Background: Bone metastasis represents an increasing clinical problem in advanced renal cell carcinoma (RCC) as disease-related survival improves. There are few data on the natural history of bone disease in...
9.
Cardillo I, Spugnini E, Galluzzo P, Contestabile M, DellAnna M, Picardo M, et al.
Future Oncol
. 2013 Aug;
9(9):1375-88.
PMID: 23980684
Aim: The aim of our study was to investigate the association of docetaxel and metronomic cyclophosphamide (CYC) in castration-resistant prostate cancer (CRPC). Materials & Methods: CRPC xenografts were established with...
10.
Santoni M, De Tursi M, Felici A, Re G, Ricotta R, Ruggeri E, et al.
Expert Rev Anticancer Ther
. 2013 Jun;
13(6):697-709.
PMID: 23773104
With seven agents approved for renal cell carcinoma within the past few years, there has undoubtedly been progress in treating this disease. However, patients with poor-risk features remain a challenging...